Preclinical efficacy: fast, reliable, decision ready data.

High-performance in vivo efficacy. Built for speed, accuracy and translational confidence.

We run predictive, high-quality preclinical efficacy studies that offer the clarity needed to make fast, confident decisions and de-risk delivery. With advanced imaging, validated models and integrated biology in-house, we deliver clean, quantitative data that stands up to investor, regulatory and clinical scrutiny.

Whether you’re screening candidates or validating a lead asset, we provide fast, reliable, decision ready efficacy data.

What we deliver

CDX, PDX and syngeneic tumour models.
Longitudinal tumour growth monitoring.
PET, SPECT/CT, IVIS and HFUS imaging.
PK/PD and therapeutic response analysis.
Combination studies and resistance profiling.
Ex vivo tissue, biomarker and phenotypic analysis.

One team. One workflow. One standard of quality.

Why work with us?

In-house specialisms: Deep radiopharmaceutical biology expertise.
Predictive models: CDX, PDX and disease-relevant systems available internally and through our partners.
Integrated imaging: PET, SPECT/CT, IVIS, HFUS.
Regulatory ready: ISO 45001 certified, licensed for alpha & beta emitters and predictive human dosimetry from pre-clinical data.
Global credibility: Our facilities are built to regulatory standards, whether your next step is the FDA, EMA or MHRA.
Translational depth: full-stack across biomarkers, ex vivo, dosimetry, radiochemistry and more.

If you need efficacy data that’s fast, clean and clinically meaningful, you need us.

World-class minds for RPT discovery and development

In the complex landscape of radiochemistry and translational imaging, the difference lies in the expertise behind the science.

Our team comprises industry-leading specialists across preclinical services and radiopharmaceuticals, dedicated to bridging the gap between early discovery and clinical success.

Meet the experts who turn sophisticated data into actionable therapeutic insights.

Explore our scientific expertise

Case study: PDX efficacy with integrated imaging

Brief: Evaluate therapeutic response in a PDX model using PET biomarkers.

We delivered:

Longitudinal PET imaging.
Quantitative tumour response curves.
Ex vivo validation.

Outcome: Clear go/no‑go decision and accelerated IND planning.

Start your project

Ready to accelerate your preclinical efficacy?

Our experts are here to support your journey from concept to clinic. Contact our team to discuss a tailored solution.

Speak to the team, we’ll scope your project and get you moving fast.

Expertise in radiolabelling

With gamma, beta and alpha-emitting radiometals of small molecules (e.g., FAPI, PSMA), peptides, proteins and other biologics containing chelators such as DOTA, DOTAM, Macropa, and DFO/DFO*. Experience in a variety of purification methods (e.g., ultrafiltration, SPE), QC analysis (HPLC, ITLC, gamma spectrometry), and conjugation techniques.

Discover more